Oncotelic and Sapu Nano to Present Deciparticle Nanomedicine Platform at BIO 2026

Oncotelic Therapeutics (OTCQB: OTLC) and Sapu Nano announced that CEO Vuong Trieu will present the Deciparticle nanomedicine platform at the BIO International Convention 2026 in San Diego. The presentation will focus on the development of ultra-small nanomedicine formulations designed to enable intravenous administration of highly water-insoluble therapeutics, addressing a key challenge in drug delivery.

The Deciparticle platform utilizes proprietary amphiphilic polymer systems capable of forming particles smaller than 20 nanometers for oncology and other therapeutic applications. The companies plan to showcase development progress across multiple Deciparticle programs, including Sapu006, a polysorbate-free intravenous docetaxel formulation moving into Phase 1b clinical evaluation, and Sapu003, an intravenous everolimus nanomedicine program currently in a global Phase 1b clinical trial.

Additionally, the presentation will highlight the integration of artificial intelligence and knowledge-organization technologies into formulation development and translational oncology workflows through the PDAOAI platform. This approach aims to accelerate drug development and improve outcomes.

The significance of this announcement lies in the potential of the Deciparticle platform to overcome solubility issues that limit the use of many potent therapeutics. By enabling intravenous delivery of water-insoluble drugs, the platform could expand treatment options for cancer and other diseases. The clinical progress of Sapu006 and Sapu003 suggests that the technology is moving toward real-world application.

Oncotelic Therapeutics is a clinical-stage biopharmaceutical company focused on oncology and immunotherapy, with a mission to address high-unmet-need cancers and rare pediatric indications. The company benefits from a portfolio of inventions by CEO Dr. Vuong Trieu, who has filed over 500 patent applications and holds 75 issued patents. Oncotelic also leverages its proprietary AI-enabled PDAOAI platform for research, biomarker discovery, and regulatory processes.

Sapu Nano is a biotechnology company developing next-generation nanomedicine platforms to improve drug delivery and enhance therapeutic index, with a primary focus in oncology. The collaboration with Oncotelic combines expertise in nanomedicine and drug development.

For more information, visit the company’s newsroom at https://ibn.fm/OTLC and view the full press release at https://ibn.fm/RUG7m.

This news story relied on content distributed by InvestorBrandNetwork (IBN). Blockchain Registration, Verification & Enhancement provided by NewsRamp. The source URL for this press release is Oncotelic and Sapu Nano to Present Deciparticle Nanomedicine Platform at BIO 2026.

The post Oncotelic and Sapu Nano to Present Deciparticle Nanomedicine Platform at BIO 2026 appeared first on citybuzz.